Modern glucagon-like peptide 1 (GLP-1) analogues and the combined gastric inhibitory polypeptide (GIP)/GLP‐1 agonist tirzepatide play an important role in the combined treatment of obesity and type 2 diabetes mellitus. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.